2
|
Langer G, Scott J, Lind C, Otto C, Bothe U, Laux-Biehlmann A, Müller J, le Roy B, Irlbacher H, Nowak-Reppel K, Schlüter A, Davenport AJ, Slack M, Bäurle S. Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor. Mol Pharmacol 2023; 104:105-114. [PMID: 37348913 DOI: 10.1124/molpharm.122.000662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 05/04/2023] [Accepted: 05/12/2023] [Indexed: 06/24/2023] Open
Abstract
The human pituitary adenylate cyclase-activating polypeptide receptor (hPAC1-R), a class B G-protein-coupled receptor (GPCR) identified almost 30 years ago, represents an important pharmacological target in the areas of neuroscience, oncology, and immunology. Despite interest in this target, only a very limited number of small molecule modulators have been reported for this receptor. We herein describe the results of a drug discovery program aiming for the identification of a potent and selective hPAC1-R antagonist. An initial high-throughput screening (HTS) screen of 3.05 million compounds originating from the Bayer screening library failed to identify any tractable hits. A second, completely revised screen using native human embryonic kidney (HEK)293 cells yielded a small number of hits exhibiting antagonistic properties (4.2 million compounds screened). BAY 2686013 (1) emerged as a promising compound showing selective antagonistic activity in the submicromolar potency range. In-depth characterization supported the hypothesis that BAY 2686013 blocks receptor activity in a noncompetitive manner. Preclinical, pharmacokinetic profiling indicates that BAY 2686013 is a valuable tool compound for better understanding the signaling and function of hPAC1-R. SIGNIFICANCE STATEMENT: Although the human pituitary adenylate cyclase-activating polypeptide receptor (hPAC1-R) is of major significance as a therapeutic target with a well documented role in pain signaling, only a very limited number of small-molecule (SMOL) compounds are known to modulate its activity. We identified and thoroughly characterized a novel, potent, and selective SMOL antagonist of hPAC1-R (acting in an allosteric manner). These characteristics make BAY 2686013 an ideal tool for further studies.
Collapse
Affiliation(s)
- Gernot Langer
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - John Scott
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Christoffer Lind
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Christiane Otto
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Ulrich Bothe
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Alexis Laux-Biehlmann
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Jörg Müller
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Beau le Roy
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Horst Irlbacher
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Katrin Nowak-Reppel
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Anne Schlüter
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Adam J Davenport
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Mark Slack
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| | - Stefan Bäurle
- Bayer AG, Research & Development, Pharmaceuticals, Berlin, Germany (G.L., U.B., J.M., B.l.R., S.B.); Bayer AG, Research & Development, Pharmaceuticals, Wuppertal, Germany (C.O., A.L.-B.); Innovation Campus Berlin, a Nuvisan Company, Berlin, Germany (H.I., K.N.-R.); Evotec SE, Hamburg, Germany (A.S., M.S.); and Evotec (UK) Ltd, Abingdon, Oxfordshire, United Kingdom (J.S., C.L., A.J.D.)
| |
Collapse
|
3
|
Serioli L, Gruzinskyte L, Zappalà G, Hwu ET, Laksafoss TZ, Jensen PL, Demarchi D, Müllertz A, Boisen A, Zór K. Moving perfusion culture and live-cell imaging from lab to disc: proof of concept toxicity assay with AI-based image analysis. LAB ON A CHIP 2023; 23:1603-1612. [PMID: 36790123 DOI: 10.1039/d2lc00984f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
Abstract
In vitro, cell-based assays are essential in diagnostics and drug development. There are ongoing efforts to establish new technologies that enable real-time detection of cell-drug interaction during culture under flow conditions. Our compact (10 × 10 × 8.5 cm) cell culture and microscope on disc (CMoD) platform aims to decrease the application barriers of existing lab-on-a-chip (LoC) approaches. For the first time in a centrifugal device, (i) cells were cultured for up to six days while a spindle motor facilitated culture medium perfusion, and (ii) an onboard microscope enabled live bright-field imaging of cells while the data wirelessly transmitted to a computer. The quantification of cells from the acquired images was done using artificial intelligence (AI) software. After optimization, the obtained cell viability data from the AI-based image analysis proved to correlate well with data collected from commonly used image analysis software. The CMoD was also suitable for conducting a proof-of-concept toxicity assay with HeLa cells under continuous flow. The half-maximal inhibitory time (IT50) for various concentrations of doxorubicin (DOX) in the case of HeLa cells in flow, was shown to be lower than the IT50 obtained from a static cytotoxicity assay, indicating a faster onset of cell death in flow. The CMoD proved to be easy to handle, enabled cell culture and monitoring without assistance, and is a promising tool for examining the dynamic processes of cells in real-time assays.
Collapse
Affiliation(s)
- Laura Serioli
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
- BioInnovation Institute Foundation, Copenhagen N 2800, Denmark
| | - Lina Gruzinskyte
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
| | - Giulia Zappalà
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
- Department of Electronics and Telecommunications, Politecnico di Torino, Italy
| | - En Te Hwu
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
| | - Trygvi Zachariassen Laksafoss
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
| | | | - Danilo Demarchi
- Department of Electronics and Telecommunications, Politecnico di Torino, Italy
| | - Anette Müllertz
- Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
| | - Anja Boisen
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
- BioInnovation Institute Foundation, Copenhagen N 2800, Denmark
| | - Kinga Zór
- The Danish National Research Foundation and Villum Foundation's Center for Intelligent Drug Delivery and Sensing Using Microcontainers and Nanomechanics (IDUN), Department of Health Technology, Technical University of Denmark, Denmark.
- BioInnovation Institute Foundation, Copenhagen N 2800, Denmark
| |
Collapse
|
5
|
Panknin O, Wagenfeld A, Bone W, Bender E, Nowak-Reppel K, Fernández-Montalván AE, Nubbemeyer R, Bäurle S, Ring S, Schmees N, Prien O, Schäfer M, Friedrich C, Zollner TM, Steinmeyer A, Mueller T, Langer G. Discovery and Characterization of BAY 1214784, an Orally Available Spiroindoline Derivative Acting as a Potent and Selective Antagonist of the Human Gonadotropin-Releasing Hormone Receptor as Proven in a First-In-Human Study in Postmenopausal Women. J Med Chem 2020; 63:11854-11881. [PMID: 32960053 DOI: 10.1021/acs.jmedchem.0c01076] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The growth of uterine fibroids is sex hormone-dependent and commonly associated with highly incapacitating symptoms. Most treatment options consist of the control of these hormonal effects, ultimately blocking proliferative estrogen signaling (i.e., oral contraceptives/antagonization of human gonadotropin-releasing hormone receptor [hGnRH-R] activity). Full hGnRH-R blockade, however, results in menopausal symptoms and affects bone mineralization, thus limiting treatment duration or demanding estrogen add-back approaches. To overcome such issues, we aimed to identify novel, small-molecule hGnRH-R antagonists. This led to the discovery of compound BAY 1214784, an orally available, potent, and selective hGnRH-R antagonist. Altering the geminal dimethylindoline core of the initial hit compound to a spiroindoline system significantly improved GnRH-R antagonist potencies across several species, mandatory for a successful compound optimization in vivo. In a first-in-human study in postmenopausal women, once daily treatment with BAY 1214784 effectively lowered plasma luteinizing hormone levels by up to 49%, at the same time being associated with low pharmacokinetic variability and good tolerability.
Collapse
Affiliation(s)
- Olaf Panknin
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Andrea Wagenfeld
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Wilhelm Bone
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Eckhard Bender
- Research & Development, Pharmaceuticals, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany
| | - Katrin Nowak-Reppel
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | | | - Reinhard Nubbemeyer
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Stefan Bäurle
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Sven Ring
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Norbert Schmees
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Olaf Prien
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Martina Schäfer
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Christian Friedrich
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Thomas M Zollner
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Andreas Steinmeyer
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| | - Thomas Mueller
- Research & Development, Pharmaceuticals, Bayer AG, Aprather Weg 18a, 42113 Wuppertal, Germany
| | - Gernot Langer
- Research & Development, Pharmaceuticals, Bayer AG, Müllerstrasse 170, 13342 Berlin, Germany
| |
Collapse
|
6
|
Bäurle S, Nagel J, Peters O, Bräuer N, ter Laak A, Preusse C, Rottmann A, Heldmann D, Bothe U, Blume T, Zorn L, Walter D, Zollner TM, Steinmeyer A, Langer G. Identification of a Benzimidazolecarboxylic Acid Derivative (BAY 1316957) as a Potent and Selective Human Prostaglandin E2 Receptor Subtype 4 (hEP4-R) Antagonist for the Treatment of Endometriosis. J Med Chem 2019; 62:2541-2563. [DOI: 10.1021/acs.jmedchem.8b01862] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Stefan Bäurle
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Jens Nagel
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Olaf Peters
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Nico Bräuer
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Antonius ter Laak
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Cornelia Preusse
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Antje Rottmann
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Dieter Heldmann
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Ulrich Bothe
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Thorsten Blume
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Ludwig Zorn
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Daryl Walter
- Evotec (UK) Ltd., 112-114 Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, U.K
| | - Thomas M. Zollner
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Andreas Steinmeyer
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| | - Gernot Langer
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13353 Berlin, Germany
| |
Collapse
|